Victoria Riedl
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Victoria Riedl has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Anat Yerushalmy-Feler
Gray Faculty of Medical and Health Sciences Tel Aviv University Tel Aviv Israel
1 shared publication - Bénédicte Pigneur
Service de Gastro‐entérologie et Nutrition pédiatrique, Centre de Référence Des Maladies Rares Digestives (MARDI), assistance Publique – Hôpitaux de Paris, Hôpital Necker Enfants Malades Université Paris Cité Paris France
1 shared publication Caterina Strisciuglio
Department of Woman, Child and General and Specialist Surgery University of Campania “Luigi Vanvitelli” Naples Italy
1 shared publication- Christian Jakobsen
Department of Pediatric and Adolescent Medicine Amager‐Hvidovre University Hospital, Copenhagen IBD Center Copenhagen Denmark
1 shared publication - Christoph Norden
Department of Pediatric and Adolescent Medicine Amager‐Hvidovre University Hospital, Copenhagen IBD Center Copenhagen Denmark
1 shared publication - Christos Tzivinikos
Paediatric Gastroenterology Department Al Jalila Children's Specialty Hospital, Mohammed Bin Rashid University Dubai United Arab Emirates
1 shared publication
Latest Publications
- Open Access
- 5 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Efficacy and safety of ustekinumab and vedolizumab in very early‐onset inflammatory bowel disease: A multicenter study from the pediatric inflammatory bowel disease Porto Group of ESPGHAN
Objective: We aimed to assess vedolizumab and ustekinumab efficacy and safety in patients with very‐early onset inflammatory bowel disease (VEO‐IBD). Methods: A retrospective study involving 29 European and North American sites affiliated with the IBD Porto Group of European Society for Paediatric Gastroenterology Hepatology and Nutrition. Clinical and laboratory data were collected from patients with VEO‐IBD who commenced vedolizumab or ustekinumab before 6 years of age, between 2014 and 2024. Results: Ninety‐six patients (60.4% females) were included (58 ulcerative colitis, 29 Crohn's disease, and 9 IBD‐Unclassified). Median (Q1–Q3) age at diagnosis was 2.3 (0.4–4.2) years, 37 (38.5%) patients were diagnosed at age <2 years old. Thirty‐seven (38.5%) patients received ustekinumab, 67 (69.7%) vedolizumab, and 11 (11.5%) both drugs. Median (Q1–Q3) follow‐up time was 11 (6–26) and 14 (7–39) months for ustekinumab and vedolizumab, respectively. Eighty (84.2%) patients were previously treated with infliximab, 23 (24.2%) with adalimumab, and 20 (20.8%) with both. The median (Q1–Q3) time from diagnosis to vedolizumab and ustekinumab initiation was 15 (9–26) and 20 (11–36) months, respectively. Ustekinumab‐treated patients achieved clinical remission in 24.3%, 51.4%, and 40.5% at end of induction, week 26, and week 52, with steroid‐free remission in 18.9%, 45.9%, and 35.3%, respectively. Vedolizumab‐treated patients achieved clinical remission in 29%, 47.5%, and 40.3%, with steroid‐free clinical remission (SFCR) rates of 10.4%, 43.3%, and 37.3% at the same time points. Infectious adverse events were reported in 3 (8.3%) of ustekinumab‐treated and 5 (7.6%) vedolizumab‐treated patients, none severe. Conclusions: Ustekinumab and vedolizumab demonstrated high therapeutic durability in patients with VEO‐IBD; 1‐year rates of SFCR were modest.
- 5 November 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
Open AccessEfficacy and safety of ustekinumab and vedolizumab in very early‐onset inflammatory bowel disease: A multicenter study from the pediatric inflammatory bowel disease Porto Group of ESPGHAN
Objective: We aimed to assess vedolizumab and ustekinumab efficacy and safety in patients with very‐early onset inflammatory bowel disease (VEO‐IBD). Methods: A retrospective study involving 29 European and North American sites affiliated with the IBD Porto Group of European Society for Paediatric Gastroenterology Hepatology and Nutrition. Clinical and laboratory data were collected from patients with VEO‐IBD who commenced vedolizumab or ustekinumab before 6 years of age, between 2014 and 2024. Results: Ninety‐six patients (60.4% females) were included (58 ulcerative colitis, 29 Crohn's disease, and 9 IBD‐Unclassified). Median (Q1–Q3) age at diagnosis was 2.3 (0.4–4.2) years, 37 (38.5%) patients were diagnosed at age <2 years old. Thirty‐seven (38.5%) patients received ustekinumab, 67 (69.7%) vedolizumab, and 11 (11.5%) both drugs. Median (Q1–Q3) follow‐up time was 11 (6–26) and 14 (7–39) months for ustekinumab and vedolizumab, respectively. Eighty (84.2%) patients were previously treated with infliximab, 23 (24.2%) with adalimumab, and 20 (20.8%) with both. The median (Q1–Q3) time from diagnosis to vedolizumab and ustekinumab initiation was 15 (9–26) and 20 (11–36) months, respectively. Ustekinumab‐treated patients achieved clinical remission in 24.3%, 51.4%, and 40.5% at end of induction, week 26, and week 52, with steroid‐free remission in 18.9%, 45.9%, and 35.3%, respectively. Vedolizumab‐treated patients achieved clinical remission in 29%, 47.5%, and 40.3%, with steroid‐free clinical remission (SFCR) rates of 10.4%, 43.3%, and 37.3% at the same time points. Infectious adverse events were reported in 3 (8.3%) of ustekinumab‐treated and 5 (7.6%) vedolizumab‐treated patients, none severe. Conclusions: Ustekinumab and vedolizumab demonstrated high therapeutic durability in patients with VEO‐IBD; 1‐year rates of SFCR were modest.
- Open Access
- 18 January 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 82 (4) , 1006-1018
Real‐world data on STRIDE‐II treatment targets in a pediatric cohort with inflammatory bowel disease
Objectives: STRIDE (selecting therapeutic targets in inflammatory bowel disease) established evidence‐based targets for treat‐to‐target strategies in inflammatory bowel disease (IBD). STRIDE‐II designates clinical remission, C‐reactive protein (CRP) normalization, and fecal calprotectin (FC) reduction as short‐ to intermediate‐term targets, and mucosal healing as a long‐term target. This study evaluated STRIDE‐II application and disease control in a real‐world pediatric cohort. Methods: We retrospectively analyzed newly diagnosed pediatric IBD patients (ages 3–18 years) treated according to guidelines between June 2017 and January 2023. Time‐to‐reach STRIDE‐II targets and time‐to‐first flare were assessed over 52 weeks using disease activity indices, inflammatory biomarkers (CRP, FC), and endoscopy. Results: Seventy‐four patients were included (37 Crohn's disease [CD], 37 ulcerative colitis [UC]). All CD patients received primary maintenance therapy with immunomodulators or biologics, versus 51% UC patients. Clinical remission and CRP normalization occurred within 5–10 weeks; FC normalization within 12–19 weeks. By 6 months, combined targets (clinical remission plus CRP and FC normalization) were achieved by 54% of CD patients and 43% of UC patients. Clinical relapse after remission occurred more frequently in UC than in CD (67% vs. 43%, p = 0.0334). Follow‐up endoscopy at a median of 41 weeks (CD) and 52 weeks (UC) showed endoscopic healing in 7/18 (39%) CD and 13/22 (59%) UC patients. Conclusions: Most pediatric IBD patients achieved clinical remission and CRP normalization within STRIDE‐II timeframes, whereas FC normalization occurred later, and relapses—particularly in UC—remained common. The notable proportion of patients with suboptimal disease control underscores the need for continuous monitoring in pediatric IBD.
- 18 January 2026
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 82 (4) , 1006-1018
Open AccessReal‐world data on STRIDE‐II treatment targets in a pediatric cohort with inflammatory bowel disease
Objectives: STRIDE (selecting therapeutic targets in inflammatory bowel disease) established evidence‐based targets for treat‐to‐target strategies in inflammatory bowel disease (IBD). STRIDE‐II designates clinical remission, C‐reactive protein (CRP) normalization, and fecal calprotectin (FC) reduction as short‐ to intermediate‐term targets, and mucosal healing as a long‐term target. This study evaluated STRIDE‐II application and disease control in a real‐world pediatric cohort. Methods: We retrospectively analyzed newly diagnosed pediatric IBD patients (ages 3–18 years) treated according to guidelines between June 2017 and January 2023. Time‐to‐reach STRIDE‐II targets and time‐to‐first flare were assessed over 52 weeks using disease activity indices, inflammatory biomarkers (CRP, FC), and endoscopy. Results: Seventy‐four patients were included (37 Crohn's disease [CD], 37 ulcerative colitis [UC]). All CD patients received primary maintenance therapy with immunomodulators or biologics, versus 51% UC patients. Clinical remission and CRP normalization occurred within 5–10 weeks; FC normalization within 12–19 weeks. By 6 months, combined targets (clinical remission plus CRP and FC normalization) were achieved by 54% of CD patients and 43% of UC patients. Clinical relapse after remission occurred more frequently in UC than in CD (67% vs. 43%, p = 0.0334). Follow‐up endoscopy at a median of 41 weeks (CD) and 52 weeks (UC) showed endoscopic healing in 7/18 (39%) CD and 13/22 (59%) UC patients. Conclusions: Most pediatric IBD patients achieved clinical remission and CRP normalization within STRIDE‐II timeframes, whereas FC normalization occurred later, and relapses—particularly in UC—remained common. The notable proportion of patients with suboptimal disease control underscores the need for continuous monitoring in pediatric IBD.